Renalytix plc (LSE: RENX; OTCQB: RNLXY), the artificial intelligence-enabled precision medicine diagnostics company focused on kidney disease management, has confirmed its 2026 Annual General Meeting will be held on Friday 11 December 2026 at 10:30 a.m. GMT. The meeting will take place at 16 Columbus Walk, Brigantine Place, Cardiff, CF10 4BY. The notice is relevant to shareholders given the company's previously announced extension of its accounting reference date, which will affect when audited accounts are next presented to investors.
Key Points
- Renalytix plc (LSE: RENX; OTCQB: RNLXY) — AI-enabled in vitro diagnostics company focused on kidney disease
- 2026 AGM confirmed for 11 December 2026 at 10:30 a.m. GMT in Cardiff
- Accounting reference date extended to 31 December 2026; audited accounts covering an 18-month period to be published by 30 June 2027
- Investors should watch for the subsequent AGM to be convened once audited accounts are laid before shareholders by 30 June 2027
Renalytix 2026 AGM Confirmed at Cardiff Venue on 11 December
Renalytix plc has formally notified shareholders that its Annual General Meeting will be held at 16 Columbus Walk, Brigantine Place, Cardiff, CF10 4BY on Friday 11 December 2026, beginning at 10:30 a.m. GMT. The full Notice of AGM has been posted to shareholders who have not consented to receive electronic communications, and is also available on the company's investor relations website. The announcement was made on 18 November 2026 and was published via the London Stock Exchange's Regulatory News Service.
18-Month Accounting Period Ending December 2026 Follows Reference Date Extension
As previously announced on 14 September 2026, Renalytix extended its accounting reference date to 31 December 2026. As a direct consequence, the company will publish audited accounts covering an 18-month period ending 31 December 2026 by 30 June 2027. A further Annual General Meeting will then be convened to lay those accounts before shareholders at that time. Investors may be watching this extended reporting timeline closely, as it means the next set of full audited financial results will not be presented until mid-2027.
KidneyIntelX Technology and Renalytix's FDA-Authorised US Commercial Position
Renalytix develops and commercialises its KidneyIntelX™ platform, an AI-driven in vitro diagnostic tool designed to assess patient-level risk of progressive decline in kidney function, particularly in early-stage diabetic kidney disease. The company states that its kidneyintelX.dkd test has received FDA authorisation and Medicare reimbursement, and is offered commercially throughout the United States. The company highlights that diabetic kidney disease affects approximately 15 million people in the United States and approximately 8 million in the United Kingdom, representing a significant addressable clinical and commercial opportunity.
Nominated Adviser and Joint Brokers Supporting Renalytix's London Listing
SP Angel Corporate Finance LLP acts as Nominated Adviser and Joint Broker to Renalytix, with Oberon Capital serving as Joint Broker. Walbrook PR Limited handles communications on behalf of the company. These adviser relationships are standard for an AIM-listed company maintaining its regulatory obligations on the London Stock Exchange. James McCullough serves as Chief Executive Officer, with media and investor enquiries directed through Walbrook PR. The company operates with offices in both London and New York, reflecting its dual UK–US commercial focus.




Please wait processing your request...